While Semaglutide GLP-1 is generally considered safe and effective for most individuals with obesity, there are certain groups of people who may not be able to use Semaglutide GLP-1 due to potential risks and contraindications
A1C reduction of 1% has been associated with meaningful reductions in diabetes-related complications
Anyone requiring insurance coverage or prescription documentation benefits from Mounjaros approved status
Explore GLP-1 medication options, the GLP-1 weight loss program, tirzepatide medication options, or the tirzepatide weight loss program
Chipping away at access and stigma, Ro partnered with Serena Williams to humanize treatment, WeightWatchers enlisted Queen Latifah for GLP-1s x menopause, and Hims acquired compounding pharmacies, despite being cut off by Novo Nordisk
obesity trial: cardiometabolic markers, liver fat reduction, lipid profiles Hepatology (2024) Triple agonists in NAFLD/NASH: hepatic steatosis resolution (preclinical and clinical evidence) The Lancet (2023) Supplementary Data Rosenstock et al